Sarcopenia is an age-related condition characterized by progressive decline in muscle mass, strength, and physical performance, contributing to frailty and adverse health outcomes. Despite increasing interest in molecular biomarkers, longitudinal data with external validation are limited. This study utilized high-throughput proteomic analysis to identify and validate biomarkers associated with progression of sarcopenia in prospective cohorts.